New dosing schedules in pre-treated patients with metastatic colorectal cancer.
作者信息
Pfeiffer Per, Tarpgaard Line Schmidt
机构信息
Department of Oncology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
出版信息
J Gastrointest Oncol. 2025 Aug 30;16(4):1773-1778. doi: 10.21037/jgo-2025-492. Epub 2025 Aug 26.
Abstract
摘要
相似文献
1
New dosing schedules in pre-treated patients with metastatic colorectal cancer.转移性结直肠癌预处理患者的新给药方案。
J Gastrointest Oncol. 2025 Aug 30;16(4):1773-1778. doi: 10.21037/jgo-2025-492. Epub 2025 Aug 26.
2
Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.呋喹替尼剂量调整在转移性结直肠癌三线治疗中的疗效与安全性：一项真实世界背景的回顾性研究
J Gastrointest Oncol. 2025 Apr 30;16(2):542-548. doi: 10.21037/jgo-2024-881. Epub 2025 Apr 27.
3
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.呋喹替尼对比安慰剂治疗难治性转移性结直肠癌患者：FRESCO-2安全性分析
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae360.
4
Evaluation of fruquintinib's efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials.呋喹替尼在难治性转移性结直肠癌中的疗效和安全性评估：一项对II期和III期随机对照试验的系统评价和荟萃分析
Clin J Gastroenterol. 2025 Feb;18(1):11-22. doi: 10.1007/s12328-024-02087-7. Epub 2024 Dec 20.
5
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.呋喹替尼在难治性转移性结直肠癌患者中的疗效和安全性：FRESCO-2研究中日本入组患者的亚组分析
Int J Clin Oncol. 2025 Sep 1. doi: 10.1007/s10147-025-02852-9.
6
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.regorafenib 与 fruquintinib 治疗转移性结直肠癌的比较：系统评价和网络荟萃分析。
J Cancer Res Clin Oncol. 2019 Sep;145(9):2313-2323. doi: 10.1007/s00432-019-02964-6. Epub 2019 Jul 5.
7
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期：FRESCO-2研究结果
ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
8
Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.使用呋喹替尼、雷替曲塞和S-1联合作为霍奇金淋巴瘤并存的转移性结直肠癌的三线治疗：一例报告
J Gastrointest Oncol. 2023 Feb 28;14(1):450-457. doi: 10.21037/jgo-23-39. Epub 2023 Feb 21.
9
Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.fruquintinib 剂量递增策略治疗老年难治性转移性结直肠癌患者的疗效和安全性：一项单臂、多中心、Ⅱ期研究。
Cancer Med. 2023 Dec;12(24):22038-22046. doi: 10.1002/cam4.6786. Epub 2023 Dec 8.
10
From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy.从实验室到临床：呋喹替尼作为结直肠癌治疗药物的研发历程。
Expert Opin Drug Discov. 2025 Sep;20(9):1099-1113. doi: 10.1080/17460441.2025.2530597. Epub 2025 Jul 11.
本文引用的文献
1
Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer.替氟尿苷-替匹嘧啶每两周给药一次可降低骨髓抑制发生率，同时维持转移性结直肠癌患者的疗效。
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf099.
2
Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.呋喹替尼剂量调整在转移性结直肠癌三线治疗中的疗效与安全性：一项真实世界背景的回顾性研究
J Gastrointest Oncol. 2025 Apr 30;16(2):542-548. doi: 10.21037/jgo-2024-881. Epub 2025 Apr 27.
3
Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview.呋喹替尼在结直肠癌中的临床进展：综述
Pharmaceuticals (Basel). 2025 Feb 19;18(2):280. doi: 10.3390/ph18020280.
4
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.转移性结直肠癌患者的晚期治疗选择：综述与循证算法
Nat Rev Clin Oncol. 2025 Jan;22(1):28-45. doi: 10.1038/s41571-024-00965-0. Epub 2024 Nov 18.
5
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
6
Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies.晚期结直肠癌的治疗选择：从近期随机研究中汲取的经验教训
Cancers (Basel). 2023 Dec 26;16(1):126. doi: 10.3390/cancers16010126.
7
Angiogenesis inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的血管生成抑制剂。
Transl Cancer Res. 2023 Dec 31;12(12):3241-3244. doi: 10.21037/tcr-23-1568. Epub 2023 Dec 26.
8
Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.fruquintinib 剂量递增策略治疗老年难治性转移性结直肠癌患者的疗效和安全性：一项单臂、多中心、Ⅱ期研究。
Cancer Med. 2023 Dec;12(24):22038-22046. doi: 10.1002/cam4.6786. Epub 2023 Dec 8.
9
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.呋喹替尼对比安慰剂用于治疗难治性转移性结直肠癌患者（FRESCO-2）：一项国际、多中心、随机、双盲、III 期研究。
Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
10
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.替氟尿苷替匹嘧啶与贝伐珠单抗治疗难治性转移性结直肠癌
N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963.
Zotero 插件